Hi kev,
I know nothing about the reproduction of antibodies, but as I see it, it is possible that the reproduction of whole antibodies (PAT-DX3) may be a more straight froward process than the production of PAT-DX1, which, in my mind would involve an additional step of cleaving the PAT-DX1 dimer from the whole PAT-DX3 antibody.
As Dr James Campbell said:
"This set-back to the timing of our PAT-DX1 program is matrial, but is offset by the significant advances being made with the PATDX3 manufacturing program and a range of business development activities.”
https://company-announcements.copyright link/asx/pab/c90da8f0-7c98-11ec-b43c-b28af01120e0.pdf
I'm guessing thet the production of PAT-DX3 is a preliminary step in the production of PAT-DX1, and the company has reported "significant advances being made with the PATDX3 manufacturing program".
On the other hand, the testing of PAT-DX1 is much further advanced than the testing of PAT-DX3, so I guess that the clinical trials for PAT-DX3 are also some way off.
- Forums
- ASX - By Stock
- Ann: PAT-DX1 engineering update
Hi kev, I know nothing about the reproduction of antibodies, but...
-
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAB (ASX) to my watchlist
|
|||||
Last
0.6¢ |
Change
-0.001(14.3%) |
Mkt cap ! $12.34M |
Open | High | Low | Value | Volume |
0.6¢ | 0.6¢ | 0.6¢ | $518 | 86.30K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 705914 | 0.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.7¢ | 1128726 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 705914 | 0.006 |
15 | 7449991 | 0.005 |
11 | 6764199 | 0.004 |
6 | 6065682 | 0.003 |
2 | 2770000 | 0.002 |
Price($) | Vol. | No. |
---|---|---|
0.007 | 1128726 | 3 |
0.008 | 2061233 | 5 |
0.009 | 431000 | 1 |
0.010 | 396000 | 5 |
0.011 | 680000 | 2 |
Last trade - 15.42pm 02/09/2024 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |